Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) is scheduled to be releasing its earnings data before the market opens on Thursday, May 9th. Analysts expect Chemomab Therapeutics to post earnings of ($0.20) per share for the quarter.
Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.14. During the same period in the prior year, the firm earned ($0.72) earnings per share. On average, analysts expect Chemomab Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Chemomab Therapeutics Trading Up 4.2 %
Shares of Chemomab Therapeutics stock opened at $0.89 on Wednesday. Chemomab Therapeutics has a 1-year low of $0.42 and a 1-year high of $1.89. The firm’s 50-day moving average price is $0.74 and its two-hundred day moving average price is $0.64. The stock has a market capitalization of $9.82 million, a price-to-earnings ratio of -0.42 and a beta of 0.39.
Analyst Ratings Changes
View Our Latest Stock Analysis on Chemomab Therapeutics
About Chemomab Therapeutics
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
Read More
- Five stocks we like better than Chemomab Therapeutics
- What Does a Stock Split Mean?
- Garmin Navigates to New Highs Driven By Wearables Trend
- What is a Dividend King?
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- How to Calculate Return on Investment (ROI)
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.